Iressa Follow-up Trial

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Provision of written informed consent to participate in the trial.

• Female or male aged 18 years and over.

• Patients with previously diagnosed cancer who have been treated with ZD1839 in a parent ZD1839 clinical trial and may benefit from continuation

Exclusion Criteria:

• Known severe hypersensitivity to ZD1839

• Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.

• Withdrawal from a parent ZD1839 trial because of tumor progress